Research on Biomarkers May Help Enrich Acclaim-1 and Acclaim-3 Lung Cancer Clinical Trials, Potentially Predicting Patient Response to REQORSA Treatment
TROP2 and PTEN Biomarkers May Predict Patient Response to Reqorsa ® Gene Therapy
Research Collaborators Identify Biomarkers that May Predict Patient Response to Reqorsa ® Gene Therapy
AUSTIN, Texas , March 10, 2026 /PRNewswire/ -- Genprex, Inc. ("Genprex" or the "Company") (NASDAQ: GNPX), a clinical-stage gene therapy company focused on developing life-changing therapies for...
Japanese Patent Covers Acclaim-3 Clinical Trial Combining REQORSA Gene Therapy with Genentech, Inc.'s Tecentriq ®
Patent Covers Acclaim-3 Clinical Trial Combining REQORSA Gene Therapy with Genentech, Inc.'s Tecentriq®
Company Achieves Clinical Development Milestones in 2025, Advances Program for Future Scale Up and Studies
Preliminary Preclinical Data Demonstrates In Vivo Proof-of-Concept for Novel Diabetes Gene Therapy in Type 2 Diabetic Non-Human Primates
Phase 1 Study in Non-Small Cell Lung Cancer Combined Reqorsa ® Gene Therapy with Tagrisso ®
New Clinical Trial Site Added for Clinical Studies of Reqorsa® Gene Therapy to Treat Lung Cancer